Pharmacogenomics of metabolic effects of rosiglitazone. - Wikidata - awgldk - TriplyDB

Pharmacogenomics of metabolic effects of rosiglitazone.

Pharmacogenomics of metabolic effects of rosiglitazone.

http://www.wikidata.org/entity/Q46679104

about

Microarray evidences the role of pathologic adipose tissue in insulin resistance and their clinical implications.Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.The beta-3 adrenergic agonist (CL-316,243) restores the expression of down-regulated fatty acid oxidation genes in type 2 diabetic mice CD36-deficient congenic strains show improved glucose tolerance and distinct shifts in metabolic and transcriptomic profiles Rosiglitazone ameliorates diffuse axonal injury by reducing loss of tau and up-regulating caveolin-1 expression.Heterozygous connexin 50 mutation affects metabolic syndrome attributes in spontaneously hypertensive rat.The evolutionary aspects of aquaporin family.Pharmacogenetic interaction between dexamethasone and Cd36-deficient segment of spontaneously hypertensive rat chromosome 4 affects triacylglycerol and cholesterol distribution into lipoprotein fractions.Pharmacogenetic model of retinoic acid-induced dyslipidemia and insulin resistance.Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin Resistance.

P2860

Q34974769-84F78CC3-9519-4565-98B2-D9EB252E654D Q35039274-F027908C-4579-431A-904C-75395E20D1FA Q35185557-F31B6A91-7F17-4EEE-9149-3BEF474FC5C1 Q36032781-4082D3FC-CBEC-4C5A-8EE9-6D8C27FB2651 Q37129771-DA97408F-1A3C-4EC4-BB81-C8004E27D5EA Q37426508-DF277C15-E9EC-4046-B50C-87BC2A89B5EC Q37819527-E0486122-3960-4186-8209-2127DDFDE7EC Q40486276-F1307CE7-70D6-41F9-8477-683FF85FE41E Q43230869-5E0AEAC0-02A3-4026-A20B-CEF589CD2A74 Q53687224-C7A70675-7ABC-4B07-BA8B-2E378A243F96

P2860

Pharmacogenomics of metabolic effects of rosiglitazone.

http://www.wikidata.org/entity/Q46679104

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Pharmacogenomics of metabolic effects of rosiglitazone.

@en

Pharmacogenomics of metabolic effects of rosiglitazone.

@nl

type

label

Pharmacogenomics of metabolic effects of rosiglitazone.

@en

Pharmacogenomics of metabolic effects of rosiglitazone.

@nl

prefLabel

Pharmacogenomics of metabolic effects of rosiglitazone.

@en

Pharmacogenomics of metabolic effects of rosiglitazone.

@nl

P1433

Q46679104-8104CD69-BE5D-42E9-A578-F121049C65E8

P1476

Q46679104-B3983A05-1699-48D2-888D-446FE413E67A

P2093

Q46679104-18B4318E-FABB-4E76-B31D-320916B6F762

Q46679104-77B6F349-7B11-4690-B73D-0DBADEB74118

Q46679104-8C958F08-E731-4549-8A68-1CF49951A274

Q46679104-9AC3FB76-4494-4838-9215-7F557C11C84F

Q46679104-C865F86A-6108-4DDE-924A-4B0476BBFEAC

Q46679104-F5C6A4A1-5EE5-4A2A-988B-6B359D19D437

P2860

Q46679104-08B758F5-F4F0-4FAE-8E04-8EDFA0E29B74

Q46679104-12DBF988-AC24-4E33-9AFF-67770CFB37B8

Q46679104-16A38091-5E59-47CF-A4DD-BD54287D3799

Q46679104-224B9EA9-1402-4C3A-BD64-72ACB2BD10F0

Q46679104-28B5E731-86CA-45CE-8D64-A5E172DBBEB1

Q46679104-2DE4A161-EB6A-4202-B462-AA798B1B00C8

Q46679104-308B7798-83E6-4D31-A851-FE915CF96E75

Q46679104-33E47876-E6AF-4975-99FE-3B7B66137472

Q46679104-3896A172-F195-408E-847E-2C38E0CCEE67

Q46679104-48411E49-509A-4C4B-B728-C92F0BCCE968

P304

Q46679104-E3F450D9-9DF0-492D-B906-C74FD43CCA29

P31

Q46679104-FFEC0277-B9F2-49EB-91C7-B1C624B262D8

P356

Q46679104-0742EF5D-8461-4895-9F74-DBB59D588F91

P433

Q46679104-AEE8AD16-0CF3-4CE5-B82E-E71A3C3BAB44

P478

Q46679104-E322E5A9-17D4-4612-8128-0C236695FFA1

P50

Q46679104-0139D0EF-4B25-48E0-B097-C45165CBE3A1

Q46679104-A5605787-9300-432A-9492-15869C158609

Q46679104-EECF4D4D-4B4B-45E8-BF7A-C113543F413F

P577

Q46679104-CA538840-86D3-4807-8B90-D48C920FF3C6

P698

Q46679104-F37B1121-6272-437F-A13E-D33072F06BCC

P921

Q46679104-64B86868-CF8C-47C5-B8A6-2B8558AFB5FC

P356

14622416.9.2.141

P1433

Pharmacogenomics

P1476

Pharmacogenomics of metabolic effects of rosiglitazone.

@en

P2093

Drahomíra Krenová

http://www.w3.org/2001/XMLSchema#string

Gilles Corbeil

http://www.w3.org/2001/XMLSchema#string

Lucie Sedová

http://www.w3.org/2001/XMLSchema#string

Ludmila Kazdová

http://www.w3.org/2001/XMLSchema#string

Olena Oliyarnyk

http://www.w3.org/2001/XMLSchema#string

Vladimír Kren

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Epidemiologic and economic consequences of the global epidemics of obesity and diabetes

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

A new mathematical model for relative quantification in real-time RT-PCR

Sucrose feeding during pregnancy and lactation elicits distinct metabolic response in offspring of an inbred genetic model of metabolic syndrome

Molecular, biochemical, and cellular characterization of epididymal ADAMs, ADAM7 and ADAM28

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Nutrient-induced insulin resistance.

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

Sequence variation in PPARG may underlie differential response to troglitazone.

P304

141-155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14622416.9.2.141

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Johanne Tremblay

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18370844

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics